{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:48:08Z","timestamp":1777078088444,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ihj.2025.12.002","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:09:26Z","timestamp":1765296566000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: A network meta-analysis of randomized trials"],"prefix":"10.1016","volume":"78","author":[{"given":"Manyata","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annu","family":"Gulia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamalesh Kumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish Datt","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti","family":"Vibha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-3946","authenticated-orcid":false,"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ihj.2025.12.002_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004301","article-title":"Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation","volume":"4","author":"Cameron","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ihj.2025.12.002_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/biomedicines11010131","article-title":"Direct oral anticoagulants for stroke prevention in special populations: beyond the clinical trials","volume":"11","author":"Carbone","year":"2023","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.ihj.2025.12.002_bib3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ihj.2025.12.002_bib4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.ihj.2025.12.002_bib5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ihj.2025.12.002_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ihj.2025.12.002_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ihj.2025.12.002_bib8","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ihj.2025.12.002_bib9","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ihj.2025.12.002_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12325-012-0026-8","article-title":"Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban","volume":"29","author":"Potpara","year":"2012","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.ihj.2025.12.002_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s13063-017-2313-9","article-title":"Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial","volume":"18","author":"\u00c5sberg","year":"2017","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.ihj.2025.12.002_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/1074248419841634","article-title":"Prescription patterns and outcomes of patients with atrial fibrillation treated with direct oral anticoagulants and warfarin: a real-world analysis","volume":"24","author":"Kattoor","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ihj.2025.12.002_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00540-022-03072-5","article-title":"Interpreting and assessing confidence in network meta-analysis results: an introduction for clinicians","volume":"36","author":"Yang","year":"2022","journal-title":"J Anesth"},{"key":"10.1016\/j.ihj.2025.12.002_bib14","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ihj.2025.12.002_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.ihj.2025.12.002_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000051263","article-title":"Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials","volume":"12","author":"Oremus","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"10.1016\/j.ihj.2025.12.002_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Res Synth Methods"},{"issue":"9","key":"10.1016\/j.ihj.2025.12.002_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.ihj.2025.12.002_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ihj.2025.12.002_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ihj.2025.12.002_bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ihj.2025.12.002_bib22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH10-07-0451","article-title":"Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation","volume":"105","author":"Chung","year":"2011","journal-title":"Thromb Haemost"},{"issue":"21","key":"10.1016\/j.ihj.2025.12.002_bib23","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.ihj.2025.12.002_bib24","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ihj.2025.12.002_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ihj.2025.12.002_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ihj.2025.12.002_bib27","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"issue":"5","key":"10.1016\/j.ihj.2025.12.002_bib28","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH11-10-0718","article-title":"Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice","volume":"107","author":"Huisman","year":"2012","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.ihj.2025.12.002_bib29","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1253\/circj.CJ-11-1140","article-title":"Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation","volume":"76","author":"Yamashita","year":"2012","journal-title":"Circ J"},{"issue":"31","key":"10.1016\/j.ihj.2025.12.002_bib30","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","article-title":"Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial","volume":"34","author":"Al-Khatib","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ihj.2025.12.002_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijcard.2013.10.062","article-title":"Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial","volume":"170","author":"Bahit","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ihj.2025.12.002_bib32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.113.000212","article-title":"Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF","volume":"6","author":"van Diepen","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10.1016\/j.ihj.2025.12.002_bib33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation","volume":"63","author":"Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ihj.2025.12.002_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ahj.2013.05.016","article-title":"Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial","volume":"166","author":"Garcia","year":"2013","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.ihj.2025.12.002_bib35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0003-4819-158-12-201306180-00003","article-title":"Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial","volume":"158","author":"Mahaffey","year":"2013","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.ihj.2025.12.002_bib36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.010","article-title":"Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF","volume":"22","author":"Tanahashi","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"4","key":"10.1016\/j.ihj.2025.12.002_bib37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"issue":"47","key":"10.1016\/j.ihj.2025.12.002_bib38","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"issue":"47","key":"10.1016\/j.ihj.2025.12.002_bib39","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ihj.2025.12.002_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ihj.2025.12.002_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/1708538113490423","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation","volume":"22","author":"Mao","year":"2014","journal-title":"Vascular"},{"issue":"8","key":"10.1016\/j.ihj.2025.12.002_bib42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ihj.2025.12.002_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study","volume":"16","author":"Dur\u00e3es","year":"2016","journal-title":"Drugs R&D"},{"issue":"25","key":"10.1016\/j.ihj.2025.12.002_bib44","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10055","key":"10.1016\/j.ihj.2025.12.002_bib45","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ihj.2025.12.002_bib46","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","article-title":"Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48)","volume":"47","author":"Rost","year":"2016","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/j.ihj.2025.12.002_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/heartjnl-2016-310358","article-title":"Effects of dabigatran according to age in atrial fibrillation","volume":"103","author":"Lauw","year":"2017","journal-title":"Heart"},{"issue":"32","key":"10.1016\/j.ihj.2025.12.002_bib48","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","article-title":"Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial","volume":"39","author":"Ezekowitz","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ihj.2025.12.002_bib49","first-page":"1598","article-title":"Asymptomatic cerebral infarction during catheter ablation for atrial fibrillation","volume":"4","author":"Kimura","year":"2018","journal-title":"JACC (J Am Coll Cardiol): Clinical Electrophysiology"},{"issue":"32","key":"10.1016\/j.ihj.2025.12.002_bib50","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/eurheartj\/ehy176","article-title":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation","volume":"39","author":"Kirchhof","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ihj.2025.12.002_bib51","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es","year":"2019","journal-title":"Clin Cardiol"},{"issue":"10206","key":"10.1016\/j.ihj.2025.12.002_bib52","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ihj.2025.12.002_bib53","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ihj.2025.12.002_bib54","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ihj.2025.12.002_bib55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3329\/uhj.v18i1.57874","article-title":"Comparison of safety and efficacy between dabigatran and rivaroxaban in nonvalvular atrial fibrillation in tertiary level hospital","volume":"18","author":"Ahasan","year":"2022","journal-title":"Univ Heart J"},{"issue":"11","key":"10.1016\/j.ihj.2025.12.002_bib56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ihj.2025.12.002_bib57","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2025.12.002_bib58","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.ihj.2025.12.002_bib59","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ihj.2025.12.002_bib60","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/heartjnl-2015-307489","article-title":"Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis","volume":"101","author":"Caldeira","year":"2015","journal-title":"Heart"},{"issue":"13","key":"10.1016\/j.ihj.2025.12.002_bib61","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","article-title":"Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation","volume":"68","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ihj.2025.12.002_bib62","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"13","author":"Ozaki","year":"2020","journal-title":"Circ: Cardiovascular Quality and Outcomes [Internet]"},{"issue":"9921","key":"10.1016\/j.ihj.2025.12.002_bib63","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ihj.2025.12.002_bib64","article-title":"Warfarin compared with non-vitamin K antagonist oral anticoagulants in subjects with liver disease and atrial fibrillation: a meta-analysis","volume":"75","author":"Su","year":"2021","journal-title":"Int J Clin Pract [Internet]"},{"key":"10.1016\/j.ihj.2025.12.002_bib65","article-title":"Effectiveness and safety of dose\u2010specific DOACs in patients with atrial fibrillation: a systematic review and network meta\u2010analysis","volume":"vol 2025","author":"Oh","year":"2025"},{"key":"10.1016\/j.ihj.2025.12.002_bib66","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.12659\/MSM.900010","article-title":"Elevated homocysteine level related to poor outcome after thrombolysis in acute ischemic stroke","volume":"22","author":"Yao","year":"2016","journal-title":"Med Sci Monit"},{"issue":"9","key":"10.1016\/j.ihj.2025.12.002_bib67","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of Nonvitamin-K antagonist oral anticoagulants versus Vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"48","author":"Ntaios","year":"2017","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.ihj.2025.12.002_bib68","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.010","article-title":"Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF","volume":"22","author":"Tanahashi","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483225004523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483225004523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:31:36Z","timestamp":1777077096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483225004523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0019483225004523"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2025.12.002","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: A network meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}